Skip to main content

Bacteriophage inhibition of antibiotic-resistant pathogenic microbes and founding for novel therapeutic strategies

Project description

Profiling a mysterious natural 'warrior' to counter antimicrobial resistance

Complex battles between single-celled organisms – bacteria and the viruses that 'eat' them (bacteriophages) – take place all around us largely unbeknownst to the average person. As antimicrobial resistance creates an ever-growing challenge to public health, harnessing these natural bacterial killers is a promising route to new therapeutics. The problem is that, although bacteriophages are the most abundant organisms in the biosphere, we have isolated very few of them and have very little idea about how they work. All that is about to change thanks to the EU-funded PHARMS project. Scientists have ambitious plans to find all possible phages of a resistant bacterial isolate, characterise the mechanisms of action, and use the new-found knowledge to design a toolkit of phage-based therapies.

Host institution

HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH
Net EU contribution
€ 1 499 650,00
Address
Ingolstadter Landstrasse 1
85764 Neuherberg
Germany

See on map

Region
Bayern Oberbayern München, Landkreis
Activity type
Research Organisations
Other funding
€ 0,00

Beneficiaries (1)

HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH
Germany
Net EU contribution
€ 1 499 650,00
Address
Ingolstadter Landstrasse 1
85764 Neuherberg

See on map

Region
Bayern Oberbayern München, Landkreis
Activity type
Research Organisations
Other funding
€ 0,00